The global starchy roots market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth.
With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each starchy roots market player in a comprehensive way.
Sweet potato, yam and potato are some of the commonly used starchy roots whose adoption rate is increasing.
Starchy roots are known to offer various health benefits with its anti-oxidative property.
Asian countries also drive the starchy roots market by consuming them in preparing medicines.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=919Plant-based diet has gained traction in recent times and many fresh food brands have launched products that contain it.
Supply chains that connect consumers directly to farms have been emerging and are paving the growth trajectory of starchy roots market.
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research London Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link Key Market Insights Over 170 RNAi therapeutics are currently under development Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage.
The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014Majority of these were patent applications (59%), followed by granted patents (40%).
USD 5.4+ billion invested by both private and public investors, since 2014Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019.
Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.
The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region.
Amongst other elements, the report features:A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).
A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Geographical RegionsEastern ChinaSouthern ChinaNorthern China Type of ProductActive Pharmaceutical Ingredients (APIs)Drug Products Type of Drug ProductSolidLiquid / Semi-SolidInjectableOthers Scale of OperationClinicalCommercial Company SizeSmallMid-SizedLarge / Very Large Key players covered in the report2Y-ChemAurisco PharmaceuticalChemPartnerDorrapharmaHubei Biocause PharmaceuticalInfoarkNingbo Menovo PharmaceuticalShandong Xinhua PharmaceuticalShanghai Acebright PharmaceuticalsSTA PharmaceuticalZhejiang Huahai Pharmaceutical For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020 – 2030HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
The global starchy roots market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth.
With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each starchy roots market player in a comprehensive way.
Sweet potato, yam and potato are some of the commonly used starchy roots whose adoption rate is increasing.
Starchy roots are known to offer various health benefits with its anti-oxidative property.
Asian countries also drive the starchy roots market by consuming them in preparing medicines.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=919Plant-based diet has gained traction in recent times and many fresh food brands have launched products that contain it.
Supply chains that connect consumers directly to farms have been emerging and are paving the growth trajectory of starchy roots market.
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research London Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link Key Market Insights Over 170 RNAi therapeutics are currently under development Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage.
The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014Majority of these were patent applications (59%), followed by granted patents (40%).
USD 5.4+ billion invested by both private and public investors, since 2014Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019.
Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.
The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region.
Amongst other elements, the report features:A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).
A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Geographical RegionsEastern ChinaSouthern ChinaNorthern China Type of ProductActive Pharmaceutical Ingredients (APIs)Drug Products Type of Drug ProductSolidLiquid / Semi-SolidInjectableOthers Scale of OperationClinicalCommercial Company SizeSmallMid-SizedLarge / Very Large Key players covered in the report2Y-ChemAurisco PharmaceuticalChemPartnerDorrapharmaHubei Biocause PharmaceuticalInfoarkNingbo Menovo PharmaceuticalShandong Xinhua PharmaceuticalShanghai Acebright PharmaceuticalsSTA PharmaceuticalZhejiang Huahai Pharmaceutical For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020 – 2030HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]